Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan

被引：0
|
作者：
Genma, Akihiko [1 ]
Nakanishi, Yoichi [2 ]
Nakagawa, Kazuhiko [3 ]
Yamamoto, Nobuyuki [4 ]
Saito, Takeshi [5 ]
Tahara, Yasuhiro [5 ]
Ohe, Yuichiro [6 ]
机构：
[1] Nippon Med Sch, Tokyo, Japan
[2] Kyushu Univ, Sch Med, Fukuoka, Japan
[3] Kindai Univ, Sch Fac Med, Higashiosaka, Osaka, Japan
[4] Wakayama Med Univ, Wakayama, Japan
[5] Ono Pharmaceut CO LTD, Osaka, Japan
[6] Natl Canc Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SPS-9
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Fingolimod in Japanese Patients with Multiple Sclerosis: Interim Analysis Results from Post-marketing Surveillance
    Kira, J.
    Fujihara, K.
    Ueda, K.
    Tajima, T.
    Ueno, M.
    Saida, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 928 - 928
  • [22] All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
    Inoue, Yoshikazu
    Azuma, Arata
    Ogura, Takashi
    Taniguchi, Hiroyuki
    Chida, Kingo
    Bando, Masashi
    Niimi, Yuka
    Kakutani, Shinichi
    Suga, Moritaka
    Sugiyama, Yukihiko
    Kudoh, Shoji
    Nukiwa, Toshihiro
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [23] Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan
    Kawasaki, Akira
    Hatake, Kiyohiko
    Matsumura, Itaru
    Izutsu, Koji
    Hoshino, Tomohiro
    Akamatsu, Ayumi
    Kakuuchi, Akito
    Tobinai, Kensei
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 667 - 676
  • [24] All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
    Kobayashi, Mana
    Kageyama, Yutaro
    Ando, Takashi
    Sakamoto, Junko
    Kimura, Shohji
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (08) : 854 - 864
  • [25] All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
    Mana Kobayashi
    Yutaro Kageyama
    Takashi Ando
    Junko Sakamoto
    Shohji Kimura
    [J]. Clinical and Experimental Nephrology, 2021, 25 : 854 - 864
  • [26] Interim analysis of post-marketing surveillance of omalizumab in Japan
    Ohta, Ken
    Yoshisue, Hajime
    Aoki, Yasuo
    Irokawa, Takuro
    Ishigaki, Masahide
    Adachi, Mitsuru
    Miyamoto, Terumasa
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [27] Safety and Effectiveness in the 3rd Year Interim Results of All-Case Surveillance for Natalizumab in Japan
    Yokoyama, K.
    Sato, R.
    Makioka, H.
    Iizuka, Y.
    Hiramatsu, K.
    Torii, S.
    Saida, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 471 - 471
  • [28] Interim Results of Natalizumab Therapy in Patients with Multiple Sclerosis from The All-Case Surveillance in Japan
    Saida, Takahiko
    Sato, Ryusuke
    Hase, Masakazu
    Ling, Yan
    Torii, Shinichi
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 337 - 337
  • [29] Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
    Kenmotsu, Hirotsugu
    Sakai, Fumikazu
    Kato, Terufumi
    Kusumoto, Masahiko
    Baba, Tomohisa
    Kuwano, Kazuyoshi
    Gemma, Akihiko
    Nakagawa, Kazuhiko
    Nakanishi, Yoichi
    Yamamoto, Nobuyuki
    Ito, Yoshihiko
    Tahara, Yasuhiro
    Ohe, Yuichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Post-marketing surveillance of the safety of levofloxacin in Japan
    Yamaguchi, Hiroki
    Kawai, Hitomi
    Matsumoto, Takuyuki
    Yokoyama, Hiroo
    Nakayasu, Toshio
    Komiya, Masahiro
    Shimada, Jingoro
    [J]. CHEMOTHERAPY, 2007, 53 (02): : 85 - 103
12345